上海市锦天城律师事务所 关于浙江向日葵大健康科技股份有限公司 2024 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江向日葵大健康科技股份有限公司 2024 年年度股东大会的 法律意见书 致：浙江向日葵大健康科技股份有限公司 根据《中华人民共和国证券法（2019 年修订）》（以下简称"《证券法》"） 《中华人民共和国公司法（2023 修订）》（以下简称"《公司法》"）和中国证 券监督管理委员会《上市公司股东大会规则》等法律、法规和其他有关规范性文 件的要求，上海市锦天城律师事务所（以下简称"本所"）接受浙江向日葵大健 康科技股份有限公司（以下简称"向日葵"或"公司"）的委托，指派律师参加 公司 2024 年年度股东大会（以下简称"本次股东大会"或"本次会议"）。 为出具本《法律意见书》，本所声明如下： 1、本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果及 ...

Group 1: Flower Market Trends - As Mother's Day approaches, the flower market in Kunming experiences a surge in consumer demand, with citizens pre-ordering flowers and gifts [1][3] - The flower consumption trend is diversifying, moving away from the traditional dominance of carnations to a variety of flowers such as lilies, peonies, sunflowers, and roses [1][11] - Flower prices are generally rising due to increased demand, with popular flowers like carnations and roses seeing price increases of 20-40 yuan per bouquet as Mother's Day approaches [7][9] Group 2: Customization and Consumer Preferences - Many flower shops are offering customization services, allowing customers to choose flower materials, packaging designs, and greeting card messages, reflecting a growing preference for unique gifts [5][11] - The overall aesthetic and uniqueness of flower arrangements are becoming more important to consumers, leading to a willingness to spend more for personalized bouquets [5][11] Group 3: Jewelry Market Trends - The jewelry market is also bustling, with brands launching promotional activities for Mother's Day, particularly in response to rising gold prices [14][18] - Due to high gold prices, consumers are shifting their preferences towards pearl and platinum jewelry, which are becoming popular choices for Mother's Day gifts [18][20] - The average price for pearl and platinum jewelry is between 1,500 to 5,000 yuan, making them more appealing compared to gold jewelry, which often exceeds 10,000 yuan [20][22]

关于子公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）子公司浙江贝得 药业有限公司于近日取得浙江省药品监督管理局换发的《药品生产许可证》，同 意《药品生产许可证》的变更申请。新证变更了生产范围（受托信息），其他内 容不变。具体登记变更事项如下： 一、变更内容 本次《药品生产许可证》变更的内容主要是委托方浙江高跖医药科技股份有 限公司的受托产品苯璜贝他斯汀口崩片，受托信息中增加了药品 GMP 符合性检 查编号、药品 GMP 符合性检查范围，药品批准文号及批准文号有效期。 证券代码：300111 证券简称：向日葵 公告编号：2025—018 浙江向日葵大健康科技股份有限公司 企业负责人：杨自英 质量负责人：章瑾 有效期至：2025 年 11 月 9 日 许可证编号：浙 20050286 分类码：AhChDh 生产地址和生产范围：浙江省绍兴市越城区袍江工业区三江路：冻干粉针剂、 原料药、片剂、硬胶囊剂*** 二、《药品生产许可证》的基本信息 企业名称：浙江贝得药业有限公司 注册地址：浙 ...

证券代码：300111 证券简称：向日葵 公告编号：2025—019 浙江向日葵大健康科技股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）第六届董事会第 五次会议审议通过了《关于召开 2024 年年度股东大会的议案》，定于 2025 年 5 月 9 日召开公司 2024 年年度股东大会。本次股东大会会议通知已于 2025 年 4 月 18 日在巨潮资讯网（http://www.cninfo.com.cn）上发布。现将会议有关事宜提示 如下： 一、召开会议的基本情况 1、股东大会届次：2024年年度股东大会 2、股东大会的召集人：本次股东大会由董事会召集，经公司第六届董事会 第五次会议决议通过。 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件和公司章程的相关规定。 4、现场会议召开时间：2025年5月9日（星期五）14:30 网络投票时间：通过深圳证券交易所交易系统进行投票的具体时间为：2025 年5月9日9 ...

Core Insights - The company reported a total revenue of 72.23 million yuan for Q1 2025, a decrease of 11.46 million yuan compared to the same period last year, representing a year-on-year decline of 13.69% [1] - The net profit attributable to shareholders was -0.13 million yuan, a decrease of 0.68 million yuan year-on-year, reflecting a significant decline of 123.77% [1] - The latest gross profit margin is 17.94%, down 4.65 percentage points from the previous quarter and down 3.69 percentage points year-on-year [2] Financial Performance - Operating cash flow was 28.30 million yuan [1] - The latest return on equity (ROE) is -0.02%, a decrease of 0.10 percentage points year-on-year [2] - The diluted earnings per share is -0.00 yuan, which is essentially flat compared to the same period last year but shows a decline of 125.00% year-on-year [2] Efficiency Metrics - The total asset turnover ratio is 0.07 times, unchanged from the previous year [2] - The inventory turnover ratio is 0.42 times, a decrease of 0.15 times year-on-year, representing a decline of 26.22% [2] Shareholder Information - The number of shareholders is 65,200, with the top ten shareholders holding 433 million shares, accounting for 33.64% of the total share capital [2] - The largest shareholder is Wu Jianlong, holding 28.7 million shares [2] Leverage - The latest debt-to-asset ratio is 16.68% [3]

Financial Performance - The company's revenue for Q1 2025 was ¥72,231,172.35, a decrease of 13.69% compared to ¥83,692,914.60 in the same period last year[2]. - The net profit attributable to shareholders was -¥130,948.16, representing a decline of 123.77% from ¥551,007.76 year-on-year[2]. - The company's basic and diluted earnings per share were both -¥0.0001, a decrease of 125.00% from ¥0.0004 in the same period last year[2]. - Net profit for the period was ¥167,587.19, down from ¥1,372,734.93, indicating a significant decline in profitability[22]. - The total comprehensive income attributable to the parent company was -127,682.16, compared to 592,027.76 in the previous period[23]. Cash Flow - The net cash flow from operating activities increased significantly by 308.41% to ¥28,296,923.31, compared to ¥6,928,601.93 in the previous year[2]. - Operating cash inflow for Q1 2025 reached ¥101.22 million, a 44.80% increase compared to ¥69.90 million in Q1 2024, primarily due to increased cash receipts from sales[12]. - Operating cash outflow for Q1 2025 was ¥72.92 million, up 15.79% from ¥62.97 million in Q1 2024, mainly due to higher cash payments for raw materials[12]. - Cash inflows from operating activities totaled 101,217,105.86, compared to 69,903,578.08 in the previous period, indicating a growth of approximately 45%[24]. - The cash outflows from operating activities amounted to 72,920,182.55, compared to 62,974,976.15 in the previous period, reflecting an increase of about 15%[24]. - The net cash flow from investing activities was -45,372,259.11, worsening from -530,279.24 in the previous period[24]. - The net cash flow from financing activities was -2,034,883.79, compared to -225,752,723.83 in the previous period, showing a significant reduction in cash outflow[24]. Assets and Liabilities - The total assets at the end of Q1 2025 were ¥987,891,994.10, down 1.12% from ¥999,118,426.12 at the end of the previous year[2]. - Total liabilities decreased to ¥164,739,264.83 from ¥176,136,550.04, reflecting a reduction of about 6.5%[18]. - The company's cash and cash equivalents showed a decrease in current assets, with total current assets at ¥775,050,956.39 compared to ¥787,898,263.37, a decline of approximately 1.6%[19]. - The total equity attributable to shareholders decreased to ¥686,117,314.46 from ¥686,244,996.62, a slight decline of about 0.02%[19]. Development and Expenditures - The company reported a significant increase in development expenditures, rising by 38.14% to ¥16,288,668.59, attributed to new capitalized R&D projects[6]. - Research and development expenses were ¥4,442,561.10, down from ¥5,674,800.96, a decrease of about 21.7% year-over-year[21]. - The company reported a significant increase in development expenditures to ¥16,288,668.59 from ¥11,791,242.79, an increase of approximately 38.5%[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was not specified, but the largest shareholder, Wu Jianlong, holds 28.79% of shares, totaling 370,630,131 shares[14]. - Wu Jianlong's shares include 245 million pledged shares, indicating a significant portion of his holdings is under collateral[14]. Other Financial Metrics - The company recorded a 100% increase in trading financial assets, amounting to ¥40,054,465.76, due to the addition of short-term trading financial products[6]. - The company’s weighted average return on equity was -0.02%, down from 0.12% year-on-year[2]. - The company’s contract liabilities increased by 76.32% to ¥1,889,987.89, reflecting an increase in advance payments received[6]. - The company reported no investment income from asset disposals in Q1 2025, contrasting with the previous year where such income was recorded[12]. - The impact of exchange rate fluctuations on cash and cash equivalents was a gain of ¥736,528.96, a 93.87% increase from ¥379,906.82 in Q1 2024[12]. - The company has not engaged in any short-term borrowing activities in Q1 2025, contrasting with the previous year where such activities generated cash inflow of ¥8.06 million[12].

浙江向日葵大健康科技股份有限公司 2024 年度董事会工作报告 （一）董事会会议召开情况 报告期内，公司董事会根据《公司法》和《公司章程》赋予的职责，严格执 行股东大会各项决议，积极推进董事会各项决议实施，及时研究和决策公司重大 事项，确保董事会运作规范、务实、高效。 2024 年召开 9 次董事会会议，审议通过了 34 项议案。董事会会议的召集、 召开程序，符合《公司法》《证券法》等法律、法规、规范性文件及《公司章程》 的规定。 2024 年董事会召开情况如下： 1、2024 年 2 月 2 日召开公司第五届董事会第二十五次会议，审议通过了以 下议案： 2024 年，浙江向日葵大健康科技股份有限公司（以下简称"公司"）董事会 严格按照《公司法》《证券法》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等法律法规以及《公司章程》《公司董事会议事规 则》等规章制度的规定，本着对公司及全体股东负责的态度，积极有效地行使董 事会职权，认真贯彻落实股东大会的各项决议，勤勉尽责地开展董事会各项工作。 现将 2024 年度董事会主要工作情况报告如下： 一、2024 年度经营情况 2024 年， ...

证券代码：300111 证券简称：向日葵 公告编号：2025—007 浙江向日葵大健康科技股份有限公司 关于公司2025年续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）于2025年4月17 日召开了第六届董事会第五次会议、第六届监事会第三次会议，审议通过了《关 于公司2025年续聘会计师事务所的议案》，拟续聘立信会计师事务所（特殊普通 合伙）（以下简称"立信"）为公司2025年度审计机构。本议案尚需提交公司股 东大会审议通过，现将相关事宜公告如下： 一、 拟续聘会计师事务所事项的情况说明 立信是一家主要为上市公司提供审计服务的会计师事务所，具有证券期货业 务从业资格，具备多年为上市公司提供优质审计服务的丰富经验和专业能力，已 连续多年为公司提供审计服务，在以往年度对公司的审计过程中尽职尽责，能够 按照中国注册会计师审计准则要求，客观、公正的对公司会计报表发表意见。为 保证审计工作的连续性，公司拟继续聘请立信为公司 2025 年度审计机构。公司 董事会提请公司股东大会授权公司管理层根据 ...